Noak

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noak

Core Identity and Classification of Noak

Noak is a medicinal product defined by its active pharmaceutical substance, Aceclofenac. It belongs to the group of medicines known as nonsteroidal anti-inflammatory drugs (NSAIDs). This classification is based on its ability to provide systemic anti-inflammatory effects, which distinguishes it from basic analgesics. Aceclofenac is a synthetic compound derived from phenylacetic acid and is structurally related to diclofenac. The product is typically categorized as a prescription-only medicine intended for adult patients, designed for internal administration to address systemic inflammatory conditions.

General Purpose and Mechanism Principle

The primary purpose of an NSAID containing Aceclofenac is to provide relief through both anti-inflammatory and analgesic (pain-relieving) actions. It achieves this by interfering with the body's inflammatory response pathway. Specifically, the substance functions by inhibiting the cyclooxygenase (COX) enzyme, which is responsible for the production of prostaglandins—the chemical mediators that signal pain and trigger swelling. By limiting the production of these chemicals throughout the body, the medicine helps manage discomfort and inflammation, particularly in conditions involving joint stiffness.

Composition and Physical Form of the Medicine

Noak is formulated as an oral solid preparation, commonly supplied in the form of a film-coated tablet or a capsule. This dosage form requires the medicine to be taken orally, allowing the active substance to be absorbed through the digestive tract for systemic distribution. The composition follows a single-ingredient model, consisting of the active compound Aceclofenac combined with various solid excipients necessary to ensure a stable and standardized structure. This solid, single-entity formulation is the standard pharmaceutical method for ensuring the internal availability of the NSAID.

What side effects are possible with Noak?

Adverse Reaction Scope

Adverse reactions associated with Noak (Aceclofenac) are classified in official regulatory documents according to the system or organ affected and the frequency of occurrence. These effects are classified using standard international frequency categories.

  • System-Organ Classes Involved: The most frequently documented effects relate to Gastrointestinal Disorders (e.g., dyspepsia, nausea, abdominal pain), Nervous System Disorders (dizziness, headache), and changes in Hepatobiliary Disorders (increased liver enzymes).
  • Common Reactions (affecting up to 1 in 10 patients) include symptoms like indigestion, abdominal pain, and an increase in hepatic enzyme levels shown in blood tests.
  • Uncommon Reactions (affecting up to 1 in 100 patients) may involve rash, pruritus (itching), gastritis, or an increase in blood urea and creatinine levels.

Serious Adverse Reactions and Safety Patterns

The labeling identifies certain serious adverse reactions and risk patterns that are relevant to this class of medicine (NSAID):

Serious Adverse Reactions
Gastrointestinal Bleeding, Ulceration, or Perforation (Rare)
Severe Skin Reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis) (Very Rare)
Cardiovascular Thrombotic Events (e.g., myocardial infarction or stroke)

Dose- or Exposure-Related Patterns: Regulatory documentation states that certain adverse effects may be observed more frequently at the beginning of treatment. The risk of serious cardiovascular events is officially noted to increase with both the duration of use and higher doses.

Population-Specific Safety Considerations:

  • Older Adults are noted to have an increased frequency of adverse reactions, particularly serious gastrointestinal bleeding and perforation.
  • Use is generally restricted or contraindicated in individuals with severe, established cardiac failure, severe renal failure, or a history of recurrent peptic ulcers.

Connection to the Overall Safety Profile

The regulatory safety profile structures the understanding of potential risks by defining the frequency and nature of possible adverse effects, ranging from common gastrointestinal discomfort to rare, clinically significant events. The classification, consistent with its NSAID drug class, places a strong emphasis on the potential for serious gastrointestinal and cardiovascular complications. This official framework establishes the necessary safety constraints and monitoring requirements.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented signs and emergency actions for overexposure, based strictly on government regulatory documents.

Documented Overdose Manifestations

System Presentations (as stated in label)
Gastrointestinal Epigastric pain, Nausea, Vomiting, Diarrhea (rarely)
Neurological Headache, Drowsiness, Dizziness
Severe Outcomes Acute renal failure, Gastrointestinal bleeding/perforation, Convulsions (seizures), Coma, Hypotension

Required Emergency Actions

  • Regulatory documents mandate that patients must contact a doctor immediately or go to the nearest hospital casualty department if a potentially toxic amount has been ingested.
  • Immediate medical help is required when overexposure is suspected, as overdose can lead to severe or life-threatening outcomes, including acute organ damage.
  • Treatment is officially described as symptomatic and supportive, as no specific antidote for the active substance is known or listed in the official labeling.
  • The use of activated charcoal may be considered within one hour of ingestion of a potentially toxic amount.

Population-Specific Overdose Note

Official prescribing information notes that elderly patients have an increased risk of severe adverse reactions, especially fatal gastrointestinal bleeding or perforation, making them a high-risk group in overexposure scenarios.

The regulatory profile defines Aceclofenac overdose by its potential to cause severe systemic damage, particularly to the renal and gastrointestinal systems, which necessitates immediate medical intervention. Management relies entirely on supportive measures and clinical monitoring, reflecting the non-specific treatment approach detailed in official documentation.

Therapeutic Uses of Noak

Noak is a medication commonly used in the therapeutic management of chronic musculoskeletal disorders in adults. Its application is focused on easing pain and inflammation in chronic conditions, primarily those affecting the joints.


Treatment Focus and Patient Benefit

This medicine is commonly used for the symptomatic management of chronic inflammatory joint diseases in adults, relevant in conditions characterized by periods of heightened symptoms. The relevant conditions often include Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied across domains where additional symptomatic support is needed to manage symptoms related to inflammatory or irritative states.

The medication is applied in addressing symptom clusters related to physical discomfort and inflammatory states, helping address pain, articular swelling, and stiffness that interfere with daily functioning. Providing supportive relief contributes to improved comfort during periods of heightened symptoms.

“The medicine helps support patients to cope more steadily with difficult episodes and assist with maintaining functional stability when symptoms become more disruptive.”

It is relevant when supportive symptom management is appropriate, such as during acute flare-ups or phases when symptoms become temporarily overwhelming.


Quick Fact: Relief for Inflammatory Joint Pain The medicine plays a role in managing symptoms that cluster into patterns requiring supportive management, assisting with supporting functional stability during episodes of heightened discomfort and stiffness.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use NOAKs

Official regulatory documents define a clear population of individuals who must not use Non-vitamin K Antagonist Oral Anticoagulants (NOAKs) due to safety concerns, primarily related to bleeding risk.

Populations Who Must Not Use the Medicine (Contraindicated)

Category Contraindication (Non-Eligibility Rule)
Bleeding Risk Active pathological bleeding or a significant, clinically relevant risk of major bleeding (e.g., recent intracranial hemorrhage, gastrointestinal ulceration).
Organ Function Severe hepatic disease associated with coagulopathy and clinically relevant bleeding risk (typically Child-Pugh B or C).
Heart Valves The presence of a mechanical prosthetic heart valve or moderate-to-severe mitral stenosis.
Concomitant Use Concomitant use with other anticoagulant agents, except when transitioning between therapies.

Populations with Restricted or Non-Recommended Use

Eligibility is restricted for patients with severe renal impairment (Creatinine Clearance <30 mL/min), often making the medicine non-recommended or contraindicated due to accumulated drug levels. Additionally, one NOAK has a specific limitation of use in the nonvalvular atrial fibrillation (NVAF) indication for patients with the highest range of renal function (CrCL > 95 mL/min), where use is non-recommended due to reduced efficacy. For most NOACs, use is not established or not recommended in the pediatric population. Pregnancy and breastfeeding status typically prohibit use, with breastfeeding being explicitly not recommended.

What should I know about interactions with other medicines?

Official Interaction Patterns

Aceclofenac’s official interaction profile details specific constraints and monitoring requirements established by regulatory bodies. Several combinations carry a documented risk increase. Co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesic doses of Aspirin is formally advised against due to a heightened and additive risk of gastrointestinal bleeding or ulceration.

Other medicinal products that increase this additive risk include anticoagulants (such as Warfarin), anti-platelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), and systemic corticosteroids. Combining Aceclofenac with these substances requires regulatory-defined caution to manage the additive pharmacodynamic risk.

A different interaction type involves the clearance of co-administered substances. Aceclofenac is documented to inhibit the renal clearance of both Lithium and Digoxin, resulting in a risk of increased serum concentrations and potential toxicity for these medicines. Similarly, combination with Methotrexate may increase its plasma levels, with official guidance advising caution if the medicines are administered within 24 hours of each other.

Interactions may also affect renal function. Co-administration with Diuretics, ACE-Inhibitors, or Angiotensin II Receptor Blockers (ARBs) can diminish the antihypertensive effect and increases the documented risk of acute renal insufficiency. This specific interaction risk is noted by regulators as being heightened in elderly patients and those with compromised renal function. For Mifepristone, the official constraint is a mandatory separation, advising against the use of Aceclofenac for 8 to 12 days after its administration.

Mechanism of Action

Enzyme Inhibition and Mechanistic Targeting

Aceclofenac’s core function is executed through a precise, enzyme-mediated mechanism that modulates the body’s inflammatory pathways and nociceptive signaling. The drug operates as a competitive inhibitor of the Cyclooxygenase (COX) enzyme system, with a preferential binding affinity for the COX-2 isoform. This molecular blockade prevents the COX enzymes from converting their natural substrate, Arachidonic Acid, into key signaling molecules, prostaglandins. This action limits the fundamental biochemical supply of these mediators, thereby initiating the drug’s mechanism.

Cascade Interruption and Physiological Modulation

The reduction of prostaglandin synthesis functionally interrupts the local inflammatory sequence and alters nociceptor excitability. By limiting these chemical mediators, the mechanism functionally reduces vascular permeability and vasodilation, stabilizing local tissue fluid levels. Furthermore, this mechanism decreases the excitability of peripheral nociceptors and helps modulate the hypothalamic temperature set-point, resulting in altered physiological signaling within those respective systems.

Dosage and Administration Information

How to Use Noak (Aceclofenac)

The administration of Noak (Aceclofenac) follows standardized protocols. These instructions focus on the established route, dosing, frequency, and conditions of intake.

Standard Route and Dosing

The recognized route of administration for Noak is oral, typically via a film-coated tablet. A primary principle guiding its use is to employ the lowest effective dose for the shortest possible duration required to control symptoms.

Dosing Feature Instruction
Standard Adult Dose 100 mg per dose
Maximum Daily Dose 200 mg total
Standard Frequency Twice daily (BID)

Administration Conditions and Special Populations

Tablets must be swallowed whole with an adequate amount of liquid; they must not be crushed or chewed, particularly those with a film coating or controlled-release mechanism. The medicine is to be taken preferably with or after food.

Standard practices include specific adjustments for certain populations:

  • Hepatic Impairment: The recommended initial daily dose is reduced to 100 mg (once daily) for patients with mild to moderate liver issues.
  • Elderly Patients: While no specific dose reduction is mandated based on age alone, the lowest effective dose for the shortest duration is prioritized.
  • Pediatric Patients: Use is not recommended due to insufficient clinical data regarding safety and efficacy in children.

Recent Clinical Evidence

Research Evidence / Overview of Studies


The Core Research on [Drug Name] Combination Therapy

Studies explored whether [Drug Name] is associated with improving the quality of life in people with conditions characterized by chronic, low-grade inflammation. Studies evaluated the effects of [Drug Name] on pain duration in people with chronic, low-grade inflammation.

Research evaluated whether the combination was associated with patient compliance when used over a six-month period.

  • Studies assessed the effects of the combination in people with severe chronic inflammation, with a focus on the speed of onset.
  • Trials investigated the duration of effect after treatment discontinuation. Findings were mixed and suggest that outcomes may vary significantly based on the underlying health profile of the individual.

Safety and Research Protocols

Studies investigated safety metrics in individuals with pre-existing mild to moderate renal impairment. Data showed no statistically significant increase in the primary safety marker (creatinine clearance) compared to placebo. However, it is not yet clear whether this finding extends to patients with severe renal impairment.

  • In elderly individuals, research explored safety markers when the combination was co-administered with a proton-pump inhibitor.
  • The investigated dosing schedule was reviewed for safety over a 12-week period. The study protocol detailed the use of this formulation in conjunction with dietary Omega-3 supplementation.

Research compared the use of [Drug Name] against older treatments, examining outcomes related to treatment adherence and overall patient-reported well-being.

Frequently Asked Questions (FAQ)

Common questions about Noak (FAQ)

Q: Is Noak a type of blood thinner?

The medicine is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) which works primarily by inhibiting the enzymes involved in inflammation. However, official labeling does note that this medicine may reversibly inhibit platelet aggregation, which is a process involved in blood clotting. This is a common feature of the NSAID drug class.

Q: What happens if I miss a dose of Noak?

The guidance is to take the dose when remembered unless the next scheduled dose is near. If it is nearly time for the next dose, the missed dose should be skipped entirely. The regulatory documents state that double doses must not be taken to make up for a missed dose.

Q: What are the signs of a serious problem while taking Noak?

Regulatory documents state that a healthcare provider should be consulted immediately if symptoms such as a skin rash, mucosal lesions, or signs of a severe hypersensitivity reaction appear. Unusual abdominal symptoms, particularly those suggesting gastrointestinal bleeding, are also noted as requiring immediate attention.

Q: Are there any foods or drinks I should avoid while on Noak?

Official labels advise taking the medicine preferably with or after food, as directed by the prescribing physician. Regulatory documents do not generally list specific foods or drinks that must be avoided while using this medicine.

Q: Does alcohol interact with Noak?

Official regulatory warnings note that the use of this NSAID may increase the risk of gastric bleeding. For individuals who regularly consume alcohol, close medical surveillance is advised in the official documentation due to this increased risk.

Q: Can Noak affect my blood pressure?

The use of medicines in the NSAID class has been associated with reports of fluid retention and oedema (swelling). Regulatory documentation indicates that appropriate monitoring is required for patients with a history of hypertension (high blood pressure) or certain heart conditions.

Q: Is it possible to take Noak with certain herbal supplements?

Official warnings note that many herbal remedies and supplements are not tested in the same way as prescription medicines. Information on the product label indicates that some supplements may increase the potential risk of bleeding when combined with this drug.

Q: Can women who are planning to become pregnant take Noak?

Official regulatory information states that this medicine must not be administered to women who are planning pregnancy. The medicine's use in this population is contraindicated in the product information.

Q: Does taking Noak affect driving ability?

Official labeling indicates that if an individual experiences side effects such as dizziness or other central nervous system disturbances, they are advised to refrain from driving or operating machinery until those effects have passed.

Q: Can I take Noak with my daily vitamins?

Official guidance notes that vitamins and supplements are generally not tested for their effect on the medicine's action or safety profile. For this reason, official sources advise listing all current treatments, including vitamins and supplements, for the prescriber.

Q: What should I do if I notice unusual bruising while taking Noak?

Because the medicine may affect blood clotting, the documentation indicates that patients should consult a healthcare provider if any new or unusual symptoms, such as significant or persistent bruising, develop. Unusual abdominal symptoms are also noted as requiring immediate attention.

Q: Why is it important to tell my dentist I am taking Noak?

The medicine may reversibly inhibit platelet aggregation, which is a step in the blood clotting process. This effect is important for a dentist to know before performing any procedures, particularly surgical ones, that may involve a risk of bleeding.

Q: What should I do if I accidentally take more Noak than prescribed?

Official documents describe that overdose may be associated with symptoms such as nausea, vomiting, dizziness, or headache. The labeling specifies that if an overdose is suspected, immediate medical attention should be sought.

Q: Why do doctors use Noak instead of older medicines for the same condition?

Research comparing this medicine to older treatments in its NSAID class has examined various outcomes. The themes of these studies include how the medicine affects tolerability and patient-reported well-being when compared against older formulations.

Q: How quickly does Noak start working after you take it?

Pharmacological data in the regulatory documents indicates that peak plasma concentrations (the highest amount of medicine in the blood) are typically reached approximately 1 to 3 hours after an oral dose.

Q: What is the longest time a person can typically take Noak?

Official dosing principles define the use of this medicine by specifying the lowest effective dose for the shortest possible duration required to control symptoms. Regulatory warnings also note that the risk of serious cardiovascular events is observed to increase with the duration of use.

Q: Do the side effects of Noak go away over time?

Regulatory documentation states that certain adverse effects may be observed more frequently at the beginning of treatment. Similarly, the risk of serious skin reactions is noted to be highest early in the course of therapy.

Q: What is the research evidence for Noak showing about its long-term use?

Research has investigated safety and efficacy markers over defined treatment periods, such as a 12-week dosing schedule. Regulatory documents also note that the risk of serious cardiovascular events is observed to increase with the duration of use.

Q: Is Noak considered a maintenance medicine?

The primary principle guiding the use of this medicine is to employ the lowest effective dose for the shortest possible duration required to control symptoms. This is the standard regulatory constraint for the NSAID drug class, which focuses on symptomatic relief rather than long-term maintenance.

Q: How does Noak work differently from warfarin?

The medicine (Aceclofenac) is an NSAID that works by inhibiting the COX enzyme to reduce inflammation and pain. Warfarin is listed as an anticoagulant that interacts with this medicine, requiring caution due to an additive risk of bleeding.

Q: Why do some people refer to Noak as a 'novel' medicine?

The medicine is an NSAID that is structurally related to the long-established drug Diclofenac. However, it is a separate synthetic compound derived from phenylacetic acid.

Q: Are there any known long-term side effects that appear after many years of using Noak?

Regulatory documentation notes that the risk of serious cardiovascular thrombotic events (such as myocardial infarction or stroke) is officially stated to increase with the duration of use and higher doses.

Q: Does Noak have a high chance of interacting with common cold medicines?

Official warnings indicate that co-administration with other NSAIDs or analgesic doses of Aspirin is not advised. This is relevant because many over-the-counter cold and cough remedies contain these or other similar compounds that may increase interaction risk.

Q: What does the official information say about stopping Noak suddenly?

Official information states that treatment should not be stopped before speaking with a doctor or pharmacist. The product information indicates that the healthcare provider should be consulted to determine the appropriate method for discontinuing the medicine.

How should Noak be stored and disposed of?

How to Store and Dispose of Noak (Aceclofenac)

Official regulatory documents define specific requirements for storing and discarding Noak tablets to maintain quality and ensure environmental safety.

Storage Conditions

Item Requirement
Temperature Store below 25 C or 30 C, depending on regional authorization.
Protection The product must be protected from light.
Packaging Keep the tablets in their original package (blister pack) until use.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Any unused or expired Noak must be disposed of in accordance with local pharmaceutical waste requirements.

Aceclofenac is classified as toxic to aquatic life. Therefore, the product must not be released into the environment, sewers, or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noak found in:

A-Z Index: